Targeted Anti‐Inflammatory Therapy in Cardiovascular Events: Challenges and Opportunities

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality globally. Emerging evidence suggests that inflammation plays a pivotal role in the pathogenesis of atherosclerosis and subsequent cardiovascular events. Traditional treatments primarily focus on lipid-lowering and antithrombotic strategies; however, these approaches do not fully address the inflammatory component of CVD. Recent advancements have highlighted the potential of targeted anti-inflammatory therapies in mitigating cardiovascular risk. This review explores the efficacy and safety of these novel therapeutic agents. Interleukin (IL)-1β inhibitors, such as canakinumab, have shown promising results in reducing recurrent cardiovascular events in post-myocardial infarction patients. By directly modulating inflammatory pathways, canakinumab significantly lowered the incidence of major adverse cardiovascular events (MACE) independent of lipid levels. Similarly, colchicine, an ancient anti-inflammatory drug, has gained renewed interest due to its efficacy in reducing cardiovascular events in patients with chronic coronary disease and recent myocardial infarction. Furthermore, emerging therapies targeting other inflammatory mediators like IL-6 and tumor necrosis factor-α are under investigation, offering additional avenues for intervention. Despite these advancements, challenges such as identifying appropriate patient populations, long-term safety, and cost-effectiveness remain. Ongoing research aims to refine these therapies, ensuring a balance between risk reduction and adverse effects. In conclusion, targeted anti-inflammatory therapy represents a promising adjunct to traditional CVD treatments, potentially revolutionizing the management of cardiovascular events. Future studies are essential to optimize these strategies and fully integrate them into clinical practice, enhancing outcomes for patients with CVD.